Search research articles
Contact Us
Filters
Showing results (51-60 of 80) with videos related to
Page
of 8
Sort By:
European Urology Oncology
|
November 18, 2025
Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study
Andrew J Armstrong, Fred Saad, Mototsugu Oya, et al.
BJU International
|
May 24, 2021
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)
Louise Emmett, Shalini Subramaniam, Anthony M Joshua, et al.
Therapeutic Advances in Medical Oncology
|
March 6, 2023
Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)
Louise Emmett, Nikeith John, Sarennya Pathmanandavel, et al.
Neuro-Oncology Practice
|
January 31, 2022
What matters for people with brain cancer? Selecting clinical quality indicators for an Australian Brain Cancer Registry
Misa Matsuyama, Mythily Sachchithananthan, Robyn Leonard, et al.
European Urology Oncology
|
April 6, 2024
Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial
Fred Saad, Andrew J Armstrong, Mototsugu Oya, et al.
The Lancet. Oncology
|
July 14, 2023
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
Laurence Albiges, Howard Gurney, Vagif Atduev, et al.
BMJ Open
|
September 14, 2018
Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV)
Antony J Mersiades, Annette Tognela, Paul S Haber, et al.
European Urology
|
July 24, 2025
First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial
Martin H Voss, Howard Gurney, Vagif Atduev, et al.
BMC Cancer
|
July 25, 2024
A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)
Primo N Lara, Luis Villanueva, Carolina Ibanez, et al.
Internal Medicine Journal
|
May 28, 2021
Business as unusual: medical oncology services adapt and deliver during COVID-19
Avraham Travers, Kim Adler, Gillian Blanchard, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 80) with videos related to
Sort By:
Page
of 8
European Urology Oncology
|
November 18, 2025
Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study
Andrew J Armstrong, Fred Saad, Mototsugu Oya, et al.
BJU International
|
May 24, 2021
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)
Louise Emmett, Shalini Subramaniam, Anthony M Joshua, et al.
Therapeutic Advances in Medical Oncology
|
March 6, 2023
Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)
Louise Emmett, Nikeith John, Sarennya Pathmanandavel, et al.
Neuro-Oncology Practice
|
January 31, 2022
What matters for people with brain cancer? Selecting clinical quality indicators for an Australian Brain Cancer Registry
Misa Matsuyama, Mythily Sachchithananthan, Robyn Leonard, et al.
European Urology Oncology
|
April 6, 2024
Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial
Fred Saad, Andrew J Armstrong, Mototsugu Oya, et al.
The Lancet. Oncology
|
July 14, 2023
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
Laurence Albiges, Howard Gurney, Vagif Atduev, et al.
BMJ Open
|
September 14, 2018
Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV)
Antony J Mersiades, Annette Tognela, Paul S Haber, et al.
European Urology
|
July 24, 2025
First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial
Martin H Voss, Howard Gurney, Vagif Atduev, et al.
BMC Cancer
|
July 25, 2024
A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)
Primo N Lara, Luis Villanueva, Carolina Ibanez, et al.
Internal Medicine Journal
|
May 28, 2021
Business as unusual: medical oncology services adapt and deliver during COVID-19
Avraham Travers, Kim Adler, Gillian Blanchard, et al.
Page
of 8